Effects of Vitamin D₃ and Marine Omega-3 Fatty Acids Supplementation on Indicated and Selective Prevention of Depression in Older Adults: Results From the Clinical Center Sub-Cohort of the VITamin D and OmegA-3 TriaL (VITAL)

Chirag M. Vyas, MBBS, MPH ; David Mischoulon, MD, PhD ; Grace Chang, MD, MPH ; Nancy R. Cook, ScD ; Alison Weinberg, MA ; Trisha Copeland, MS, RD ; Jae H. Kang, ScD ; Vadim Bubes, PhD ; Georgina Friedenberg, MPH ; Meryl S. LeBoff, MD ; I-Min Lee, MBBS, ScD ; Julie E. Buring, ScD ; JoAnn E. Manson, MD, DrPH ; Charles F. Reynolds III, MD ; Olivia I. Okereke, MD, SM

J Clin Psychiatry 2023;84(4):22m14629

ABSTRACT

Objective: To test vitamin D₃ and omega-3 fatty acids (omega-3s) for late-life depression prevention under the National Academy of Medicine framework for indicated (targeting subthreshold depression) and selective (targeting presence of high-risk factors) prevention.

Methods: The VITamin D and OmegA-3 TriaL (VITAL) is a 2 × 2 factorial trial of vitamin D₃ (2,000 IU/d) and/or omega-3s (1 g/d) for cardiovascular and cancer prevention (enrollment: November 2011–March 2014; end date: December 31, 2017). In this targeted prevention study, we included 720 VITAL clinical sub-cohort participants who completed neurobehavioral assessments at baseline and 2 years (91.9% retention). High-risk factors were subthreshold or clinical anxiety, impaired activities of daily living, physical/functional limitation, medical comorbidity, cognitive impairment, caregiving burden, problem drinking, and low psychosocial support. Coprimary outcomes were incident major depressive disorder (MDD), adjudicated using DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition), and change in mood (Patient Health Questionnaire-9 [PHQ-9]). We used exact tests to determine treatment effects on MDD incidence and repeated-measures models to determine treatment effects on PHQ-9.

Results: A total of 11.1% had subthreshold depression, 60.8% had ≥ 1 high-risk factor, MDD incidence was 4.7% (5.1% among completers), and mean PHQ-9 score change was 0.02 points. Among those with subthreshold depression, the MDD risk ratio (95% confidence interval) was 0.36 (0.06 to 1.28) for vitamin D₃ and 0.85 (0.25 to 2.92) for omega-3s, compared to placebo; results were also null among those with ≥ 1 high-risk factor (vitamin D₃ vs placebo: 0.63 [0.25 to 1.53]; omega-3s vs placebo: 1.08 [0.46 to 2.71]). There were no significant differences in PHQ-9 score change comparing either supplement with placebo.

Conclusions: Neither vitamin D₃ nor omega-3s showed benefits for indicated and selective prevention of late-life depression; statistical power was limited.

Trial Registration: ClinicalTrials.gov identifier: NCT01696435

J Clin Psychiatry 2023;84(4):22m14629

Author affiliations are listed at the end of this article.

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Buy PDF for $40

Please sign in or purchase this PDF for $40.

References (49)

Committee on Prevention of Mental Disorders. Institute of Medicine. Reducing Risks for Mental Disorders: Frontiers for Preventive Intervention Research. Washington, DC: National Academy Press; 1994.
Schoevers RA, Smit F, Deeg DJ, et al. Prevention of late-life depression in primary care: do we know where to begin? Am J Psychiatry. 2006;163(9):1611–1621. PubMed CrossRef
Smits F, Smits N, Schoevers R, et al. An epidemiological approach to depression prevention in old age. Am J Geriatr Psychiatry. 2008;16(6):444–453. PubMed CrossRef
Muñoz RF, Cuijpers P, Smit F, et al. Prevention of major depression. Annu Rev Clin Psychol. 2010;6(1):181–212. PubMed CrossRef
Lee SM, Te S, Breen EC, et al. Circulating versus lipopolysaccharide-induced inflammatory markers as correlates of subthreshold depressive symptoms in older adults. World J Biol Psychiatry. 2020;21(8):634–641. PubMed CrossRef
Brinkley TE, Leng X, Miller ME, et al. Chronic inflammation is associated with low physical function in older adults across multiple comorbidities. J Gerontol A Biol Sci Med Sci. 2009;64A(4):455–461. PubMed CrossRef
Bertone-Johnson ER. Vitamin D and the occurrence of depression: causal association or circumstantial evidence? Nutr Rev. 2009;67(8):481–492. PubMed CrossRef
Cherniack EP, Troen BR, Florez HJ, et al. Some new food for thought: the role of vitamin D in the mental health of older adults. Curr Psychiatry Rep. 2009;11(1):12–19. PubMed CrossRef
Nestler EJ, Barrot M, DiLeone RJ, et al. Neurobiology of depression. Neuron. 2002;34(1):13–25. PubMed CrossRef
Su KP, Matsuoka Y, Pae CU. Omega-3 polyunsaturated fatty acids in prevention of mood and anxiety disorders. Clin Psychopharmacol Neurosci. 2015;13(2):129–137. PubMed CrossRef
van’t Veer-Tazelaar PJ, van Marwijk HW, van Oppen P, et al. Stepped-care prevention of anxiety and depression in late life: a randomized controlled trial. Arch Gen Psychiatry. 2009;66(3):297–304. PubMed CrossRef
Sriwattanakomen R, Ford AF, Thomas SB, et al. Preventing depression in later life: translation from concept to experimental design and implementation. Am J Geriatr Psychiatry. 2008;16(6):460–468. PubMed CrossRef
Rovner BW, Casten RJ, Hegel MT, et al. Preventing depression in age-related macular degeneration. Arch Gen Psychiatry. 2007;64(8):886–892. PubMed CrossRef
Cuijpers P, Pineda BS, Quero S, et al. Psychological interventions to prevent the onset of depressive disorders: a meta-analysis of randomized controlled trials. Clin Psychol Rev. 2021;83:101955. PubMed CrossRef
Okereke OI, Lyness JM, Lotrich FE, et al. Depression in late-life: a focus on prevention. Focus Am Psychiatr Publ. 2013;11(1):22–31. PubMed CrossRef
de Koning EJ, Lips P, Penninx BWJH, et al. Vitamin D supplementation for the prevention of depression and poor physical function in older persons: the D-Vitaal study, a randomized clinical trial. Am J Clin Nutr. 2019;110(5):1119–1130. PubMed CrossRef
Bot M, Brouwer IA, Roca M, et al; MooDFOOD Prevention Trial Investigators. Effect of multinutrient supplementation and food-related behavioral activation therapy on prevention of major depressive disorder among overweight or obese adults with subsyndromal depressive symptoms: the MooDFOOD randomized clinical trial. JAMA. 2019;321(9):858–868. PubMed CrossRef
Grant AM, Avenell A, Campbell MK, et al; RECORD Trial Group. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet. 2005;365(9471):1621–1628. PubMed CrossRef
Jorde R, Sneve M, Figenschau Y, et al. Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: randomized double blind trial. J Intern Med. 2008;264(6):599–609. PubMed CrossRef
Andreeva VA, Galan P, Torrès M, et al. Supplementation with B vitamins or n-3 fatty acids and depressive symptoms in cardiovascular disease survivors: ancillary findings from the SUpplementation with FOLate, vitamins B-6 and B-12 and/or OMega-3 fatty acids (SU.FOL.OM3) randomized trial. Am J Clin Nutr. 2012;96(1):208–214. PubMed CrossRef
Giltay EJ, Geleijnse JM, Kromhout D. Effects of n-3 fatty acids on depressive symptoms and dispositional optimism after myocardial infarction. Am J Clin Nutr. 2011;94(6):1442–1450. PubMed CrossRef
Zimmer R, Riemer T, Rauch B, et al; OMEGA-Study Group. Effects of 1-year treatment with highly purified omega-3 fatty acids on depression after myocardial infarction: results from the OMEGA trial. J Clin Psychiatry. 2013;74(11):e1037–e1045. PubMed CrossRef
Chang SC, Pan A, Kawachi I, et al. Risk factors for late-life depression: a prospective cohort study among older women. Prev Med. 2016;91:144–151. PubMed CrossRef
Manson JE, Bassuk SS, Lee IM, et al. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials. 2012;33(1):159–171. PubMed CrossRef
Okereke OI, Reynolds CF 3rd, Mischoulon D, et al. The VITamin D and OmegA-3 TriaL-Depression Endpoint Prevention (VITAL-DEP): Rationale and design of a large-scale ancillary study evaluating vitamin D and marine omega-3 fatty acid supplements for prevention of late-life depression. Contemp Clin Trials. 2018;68:133–145. PubMed CrossRef
Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22–33, quiz 34–57. PubMed
Brown LM, Schinka JA, Mortimer JA, et al. 3MS normative data for elderly African Americans. J Clin Exp Neuropsychol. 2003;25(2):234–241. PubMed CrossRef
Bassuk SS, Murphy JM. Characteristics of the Modified Mini-Mental State Exam among elderly persons. J Clin Epidemiol. 2003;56(7):622–628. PubMed CrossRef
Manson JE, Cook NR, Lee IM, et al; VITAL Research Group. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med. 2019;380(1):33–44. PubMed CrossRef
Okereke OI, Reynolds CF 3rd, Mischoulon D, et al. Effect of long-term vitamin D3 supplementation vs placebo on risk of depression or clinically relevant depressive symptoms and on change in mood scores: a randomized clinical trial. JAMA. 2020;324(5):471–480. PubMed CrossRef
Judd LL, Rapaport MH, Paulus MP, et al. Subsyndromal symptomatic depression: a new mood disorder? J Clin Psychiatry. 1994;55(suppl):18–28. PubMed
Rapaport MH, Judd LL, Schettler PJ, et al. A descriptive analysis of minor depression. Am J Psychiatry. 2002;159(4):637–643. PubMed CrossRef
Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–613. PubMed CrossRef
Kroenke K, Strine TW, Spitzer RL, et al. The PHQ-8 as a measure of current depression in the general population. J Affect Disord. 2009;114(1-3):163–173. PubMed CrossRef
Plummer F, Manea L, Trepel D, et al. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. Gen Hosp Psychiatry. 2016;39:24–31. PubMed CrossRef
Spitzer RL, Kroenke K, Williams JBW, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–1097. PubMed CrossRef
Fillenbaum GG, Smyer MA. The development, validity, and reliability of the OARS multidimensional functional assessment questionnaire. J Gerontol. 1981;36(4):428–434. PubMed CrossRef
Bush K, Kivlahan DR, McDonell MB, et al. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med. 1998;158(16):1789–1795. PubMed CrossRef
Haley SM, McHorney CA, Ware JE Jr. Evaluation of the MOS SF-36 physical functioning scale (PF-10), I: unidimensionality and reproducibility of the Rasch item scale. J Clin Epidemiol. 1994;47(6):671–684. PubMed CrossRef
Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry. 1987;48(8):314–318. PubMed
Ryan J, Woods RL, Britt C, et al; ASPREE Investigator Group. Normative performance of healthy older individuals on the Modified Mini-Mental State (3MS) examination according to ethno-racial group, gender, age, and education level. Clin Neuropsychol. 2019;33(4):779–797. PubMed CrossRef
Higginson IJ, Gao W, Jackson D, et al. Short-form Zarit Caregiver Burden Interviews were valid in advanced conditions. J Clin Epidemiol. 2010;63(5):535–542. PubMed CrossRef
Koenig HG, Westlund RE, George LK, et al. Abbreviating the Duke Social Support Index for use in chronically ill elderly individuals. Psychosomatics. 1993;34(1):61–69. PubMed CrossRef
Strodl E, Kenardy J. The 5-item Mental Health Index predicts the initial diagnosis of nonfatal stroke in older women. J Womens Health (Larchmt). 2008;17(6):979–986. PubMed CrossRef
Fitzmaurice GM, Laird NM, Ware JH. Modelling the mean: analyzing response profiles. In: Fitzmaurice GM, Laird NM, Ware JH, eds. Applied Longitudinal Analysis. Hoboken, NJ: John Wiley & Sons; 2004:103–139.
Okereke OI, Singh A. The role of vitamin D in the prevention of late-life depression. J Affect Disord. 2016;198:1–14. PubMed CrossRef
Sinn N, Milte CM, Street SJ, et al. Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial. Br J Nutr. 2012;107(11):1682–1693. PubMed CrossRef
Whiteford HA, Harris MG, McKeon G, et al. Estimating remission from untreated major depression: a systematic review and meta-analysis. Psychol Med. 2013;43(8):1569–1585. PubMed CrossRef
Bai ZG, Bo A, Wu SJ, et al. Omega-3 polyunsaturated fatty acids and reduction of depressive symptoms in older adults: a systematic review and meta-analysis. J Affect Disord. 2018;241:241–248. PubMed CrossRef